SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
By C. K. Wibmer, F. Ayres, T. Hermanus, Mashudu Madzivhandila, Prudence Kgagudi, B. Oosthuysen, B. Lambson, Túlio de Oliveira, M. Vermeulen, Karin van der Berg and 9 more. Nature Medicine, 2021
1,170 citations recorded by the source corpus.
SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines. Substitutions in SARS-CoV-2 spike protein present in the B.1.351 variant first detected in South Africa, when expressed in pseudoviruses, mediate escape from neutralization by monoclonal antibodies under clinical development and by plasma from individuals previously infected with SARS-CoV-2, but do not prevent binding of convalescent plasma to recombinant spike protein containing B.1.351 lineage substitutions.
Subfields: Animal Science and Zoology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/439ca080d2add0ddc418fb742feff7c1b9b478a5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil (2021, background): “Moreover, E484K is associated with reduced antibody neutralisation (6, 56-58).”
- Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity (2021, neutral): “…RBD mutations, K417N, E484K, and N501Y, in addition to several mutations outside of RBD, and several reports have suggested that convalescent and vaccinee sera have decreased cross-neutralization of B.1.351 lineage variants (P. Wang et al. 2021; Wibmer et al. 2021; Wu et al. 2021; Hu et al. 2021).”
- Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2022, neutral): “Both the Beta and Delta variants are associated with decreased neutralization by some anti–receptor-binding domain and anti–N-terminal domain monoclonal antibodies, although both Beta and Delta remain responsive to at least one anti–receptor-binding domain (8, 9, 21).”